If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy assign code Z51.0, Encounter for antineoplastic radiation therapy, or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy as the first-listed or principal diagnosis.
Diagnosis Index entries containing back-references to Z51.11: Chemotherapy (session) (for) cancer Z51.11 Encounter (with health service) (for) Z76.89 ICD-10-CM Diagnosis Code Z76.89 Maintenance (encounter for) antineoplastic chemotherapy Z51.11
Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z08 became effective on October 1, 2021. This is the American ICD-10-CM version of Z08 - other international versions of ICD-10 Z08 may differ.
The guidelines are based on the coding and sequencing instructions from the Tabular List and the Alphabetic Index in ICD-10-CM. These guidelines are for medical coders who are assigning diagnosis codes in a hospital, outpatient setting, doctor’s office or some other patient setting.
Encounter for follow-up examination after completed treatment for malignant neoplasm. Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
ICD-10 code Z92. 21 for Personal history of antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
11, Encounter for antineoplastic chemotherapy; or Z51. 12, encounter of antineoplastic immunotherapy as the first-listed or principal diagnosis.
If a patient is admitted only to receive chemotherapy, sequence code V58. 11 as the principal diagnosis.
ICD-10-CM Code for Encounter for examination for admission to educational institution Z02. 0.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis followed by the appropriate code for the anemia (such as D63. 0, Anemia in neoplastic disease).
Antineoplastic chemotherapy drugs are a type of medication that doctors use to treat cancer. They contain chemicals that kill cells that rapidly divide, including cancer cells.
Chemotherapy administration codes, 96400 through 96450, 96542, 96545, and 96549, are only to be used when reporting chemotherapy administration when the drug being used is an anti-neoplastic and the diagnosis is cancer.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
Z03. 89 No diagnosis This diagnosis description is CHANGED from “No Diagnosis” to “Encounter for observation for other suspected diseases and conditions ruled out.” established. October 1, 2019, with the 2020 edition of ICD-10-CM.
Z76. 89 is a valid ICD-10-CM diagnosis code meaning 'Persons encountering health services in other specified circumstances'. It is also suitable for: Persons encountering health services NOS.
9: Fever, unspecified.
Antineoplastic chemotherapy drugs are a type of medication that doctors use to treat cancer. They contain chemicals that kill cells that rapidly divide, including cancer cells.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
A type 1 excludes note indicates that the code excluded should never be used at the same time as Z08. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition. aftercare following medical care (.
When a primary malignancy has been excised but further treatment, such as an additional surgery for the malignancy, radiation therapy or chemotherapy is directed to that site, the primary malignancy code should be used until treatment is completed.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.